These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 22924950

  • 1. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M.
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [Abstract] [Full Text] [Related]

  • 2. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
    Huang J, Cowper S, Moss J, Girardi M.
    J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P.
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [Abstract] [Full Text] [Related]

  • 4. Interventions for mycosis fungoides.
    Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T.
    Cochrane Database Syst Rev; 2020 Jul 07; 7(7):CD008946. PubMed ID: 32632956
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Jul 07; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 6. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK, Lebwohl M.
    J Drugs Dermatol; 2002 Sep 07; 1(2):134-6. PubMed ID: 12847736
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.
    Am J Clin Dermatol; 2008 Sep 07; 9(3):169-73. PubMed ID: 18429646
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
    Ponte P, Serrão V, Apetato M.
    J Eur Acad Dermatol Venereol; 2010 Jun 07; 24(6):716-21. PubMed ID: 19929938
    [Abstract] [Full Text] [Related]

  • 9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun 07; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 10. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
    Soung J, Muigai W, Amin N, Stern DK, Lebwohl MG.
    J Drugs Dermatol; 2005 Jun 07; 4(3):290-4. PubMed ID: 15898283
    [Abstract] [Full Text] [Related]

  • 11. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD.
    Arch Dermatol; 1993 Jun 07; 129(6):747-52. PubMed ID: 8507078
    [Abstract] [Full Text] [Related]

  • 12. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study.
    El-Mofty M, El-Darouty M, Salonas M, Bosseila M, Sobeih S, Leheta T, Nada H, Tawdy A, Amin I, El-Enany G.
    Photodermatol Photoimmunol Photomed; 2005 Dec 07; 21(6):281-6. PubMed ID: 16313238
    [Abstract] [Full Text] [Related]

  • 13. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May 07; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 14. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C, Gurioli C, Neri I.
    J Dermatolog Treat; 2010 Jan 07; 21(1):45-8. PubMed ID: 19603308
    [Abstract] [Full Text] [Related]

  • 15. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
    Wozniak MB, Tracey L, Ortiz-Romero PL, Montes S, Alvarez M, Fraga J, Fernández Herrera J, Vidal S, Rodriguez-Peralto JL, Piris MA, Villuendas Deceased R.
    Br J Dermatol; 2009 Jan 07; 160(1):92-102. PubMed ID: 18945306
    [Abstract] [Full Text] [Related]

  • 16. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides.
    Michaelis S, Cozzio A, Kempf W, Graf P, Burg G, Dummer R.
    Dermatology; 2004 Jan 07; 209(1):72-4. PubMed ID: 15237276
    [No Abstract] [Full Text] [Related]

  • 17. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides.
    Pavlotsky F, Hodak E, Ben Amitay D, Barzilai A.
    J Am Acad Dermatol; 2014 Sep 07; 71(3):536-41. PubMed ID: 24836546
    [Abstract] [Full Text] [Related]

  • 18. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M, García-Arpa M, González-García J.
    Int J Dermatol; 2007 Jan 07; 46(1):99-102. PubMed ID: 17214731
    [Abstract] [Full Text] [Related]

  • 19. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
    Weber F, Schmuth M, Sepp N, Fritsch P.
    Acta Derm Venereol; 2005 Jan 07; 85(4):329-32. PubMed ID: 16191854
    [Abstract] [Full Text] [Related]

  • 20. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands.
    Hernández Z, Peñate Y, Hernández-Machín B, Pérez-Méndez L, Suárez-Hernández J, Hernández J, Fernández-de-Misa R.
    Int J Dermatol; 2014 Nov 07; 53(11):1417-22. PubMed ID: 24697305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.